A Study of ZN-c3 in Subjects With Malignant Tumors
Status:
Not yet recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
This is a Phase 2 open-label, multicenter study to evaluate the clinical activity, safety,
pharmacokinetics (PK), and biomarker profile of ZN-c3 in subjects with locally advanced or
metastatic solid tumor malignancies harboring biomarkers related to deoxyribonucleic acid
(DNA) damage pathways